Cervical dysplasia support and prevention

Marketing indication for I3C and DIM. Manufacturers cite a small RCT (Bell 2000) in CIN II–III patients where I3C 200–400 mg/day showed lesion regression. The NCI 2018 review considers the data insufficient for clinical recommendations.

ICD-10 N871 drug

Also known as: CIN, Cervical intraepithelial neoplasia, HPV nutritional support

Drugs used for this condition

DIndole-3-carbinol (I3C)Case-by-case decision · Plant indole derivative from cruciferous vegetables (food supplement under Spanish RD 1487/2009)I3C was tested in a small placebo-controlled RCT (Bell 2000) in 30 patients with CIN II-III: doses of 200 and 400 mg/day for 12 weeks produced lesion regression more often than placebo. That remains the only relatively quality study. The NCI 2018 review of nutraceuticals with alleged cancer-prevention activity noted that the data are insufficient for clinical recommendations. SEGO 2024 and AEPCC do not mention I3C in cervical dysplasia management. If a patient receives a CIN diagnosis, the standard of care is observation, colposcopy and, when indicated, conization; I3C replaces neither observation nor active treatment. Discuss with the gynaecologist the standard of care for your case.

How to read tiers A–F

Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit